27th Oct 2026 12:23
Verici Dx plc
(“Verici Dx” or the “Company”)
Result of General Meeting
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the General Meeting ("GM") held earlier today, all resolutions, as set out in the GM notice published on 9 October 2026, were duly passed on a poll. Resolution 1 was passed as an ordinary resolution and Resolution 2 was passed as a special resolution.
The voting results of the GM were as follows:
| In Favour | Against | Withheld | ||
Resolution | Votes | % | Votes | % | Votes |
1 authority for the Directors to allot and issue up to 4,250,000,000 new Ordinary Shares | 1,899,022,016 | 99.94 | 1,159,788 | 0.06 | 513 |
2 to disapply the statutory pre-emption rights in connection with the issue of up to 4,250,000,000 new Ordinary Shares. | 1,898,541,608 | 99.91 | 1,639,426 | 0.09 | 1,283 |
Admission and Total Voting Rights
Application has been made to the London Stock Exchange for admission of the 2,567,000,000 Conditional Placing Shares and 124,999,983 WRAP Retail Offer Shares to trading on AIM (“Second Admission”). It is expected that Second Admission will become effective and that trading will commence in the Conditional Placing Shares and WRAP Retail Offer Shares at 8.00 a.m. on 28 October 2026.
Following Second Admission, the total issued share capital of the Company will consist of 6,662,311,370 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company will be 6,662,311,370. With effect from Second Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The new Ordinary Shares will be fully paid and will rank pari passu in all respects with each other and with the existing Ordinary Shares of the Company.
Capitalised terms not defined in this statement have the same meaning as given to them in the Company's Circular dated 9 October 2026.
Enquiries:
Verici Dx plc
| www.vericidx.com | |
Sara Barrington, CEO Julian Baines, Chairman | Via Walbrook PR | |
|
| |
Singer Capital Markets (Nominated Adviser, Joint Broker & Joint Bookrunner) | Tel: +44 (0)20 7496 3000 | |
Russell Cook / Anastassiya Eley / Harry Littlewood |
| |
|
| |
Oberon Capital (Joint Broker & Joint Bookrunner) | Tel: +44 (0)20 3179 0500 | |
Mike Seabrook / Heena Karani |
| |
|
| |
Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or [email protected] | |
Alice Woodings / Rachel Broad | Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393 | |
|
| |
| ||
Verici Dx
Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines transcriptomic analysis with proprietary tests with underlying technology based upon artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.
Operating at the intersection of laboratory and data science, Verici Dx develops complex models that the Company believes answer the clinical questions that matter most with clarity and precision. All commercially available tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.
The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.
Related Shares:
Verici Dx